NRG-GY001: A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum

Principal Investigator/Co-Principal Investigator

John H Farley, MD/Panagiotis Konstantinopoulos, MD, PhD

Primary Objective

To evaluate the anti-tumor activity of cabozantinib (XL184) in women with persistent or recurrent clear cell ovarian cancer, based on the proportion of patients who survive progression-free for at least 6 months and the proportion who have objective tumor response (complete or partial).

Patient Population

Women with recurrent, clear cell carcinoma of the ovary, fallopian tube, or peritoneum

Target Accrual

34 patients                                        


Closed: October 31, 2016

Temporarily Closed: November 30, 2015

Activated: April 1, 2015

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website

CTEP Approval Letter (pdf)


Copyright 2017 by NRG Oncology